Clinical Trials Market to reach USD 78.3 Bn by 2029 at a growth rate of 6.1 percent over the forecast period
Pune, June 08, 2023 (GLOBE NEWSWIRE) -- Maximize Market Research, a global Healthcare market research firm, has published a competitive intelligence and market research report on “Clinical Trials...
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
June 05, 2023 06:45 ET | Synlogic, Inc.
Registrational study designed to support BLA submission of first-in-class biotherapeutic Company further streamlining organization to focus resources on execution of late clinical-stage programs in...
Director of the Ivy Brain Tumor Center and director of neurosurgical oncology at Barrow Neurological Institute
Ivy Brain Tumor Center Announces Interim Results of Two Clinical Trials Targeting High-Grade Glioma
June 02, 2023 15:50 ET | Ivy Brain Tumor Center
Phoenix, AZ, June 02, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the nation’s largest early-phase drug development program dedicated to brain cancer, is...
BioNTech and OncoC4
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
June 02, 2023 06:45 ET | BioNTech SE
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications,...
BioNTech und OncoC4
BioNTech und OncoC4 präsentieren positive Phase-1/2-Daten für Antikörperkandidaten BNT316/ONC-392 bei schwer behandelbarem nicht-kleinzelligen Lungenkarzinom auf ASCO-Jahrestagung
June 02, 2023 06:45 ET | BioNTech SE
BNT316/ONC-392 ist ein innovativer monoklonaler anti-CTLA-4-Antikörperkandidat, der gemeinsam von BioNTech und OncoC4 als Mono- oder Kombinationstherapie zur Behandlung verschiedener solider...
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment
June 01, 2023 18:14 ET | Bluejay Therapeutics
SAN MATEO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a company dedicated to developing innovative treatments for viral and liver diseases, announces the successful completion...
MNPR Triangle 2.JPG
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
June 01, 2023 07:00 ET | Monopar Therapeutics Inc.
Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort achieved stable...
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
May 31, 2023 09:15 ET | Biostage, Inc.
HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs...
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
May 31, 2023 06:30 ET | Marker Therapeutics
HOUSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Coave Logo.png
Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
May 31, 2023 06:00 ET | Coave Therapeutics
CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile Positive results from the study to date support preparations for a...